Overview

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.

Phase:

Phase 4

Details

Lead Sponsor:

SK Chemicals Co., Ltd.

Treatments:

Benserazide, levodopa drug combination